Level 1,2: Stop interferon. When symptoms < Level 
1, restart at 50% of the original dose; 
Neurotoxicity Level 2: Discontinue interferon. 
2 . G-CSF 
Grade 3 toxicity (see appendix for toxicity 
levels, the hematologic portion will not be 
utilized for dose adjustments) thought to be 
related to G-CSF, will necessitate a 50% dosage 
reduction. If grade 3 toxicity persists for seven 
days or advances to grade 4 toxicity, G-CSF will 
be discontinued and the patient will not re-start 
the medication. 
12.0 HAZARDS AND DISCOMFORTS 
Detailed toxicity data on all required non-standard study 
drugs are given for each drug in the appendix. A detailed 
toxicity profile of total body irradiation at the doses and 
rates employed in this study are also given in the appendix. 
The major hazard of this protocol is transplant-related 
morbidity and mortality. The marrow ablative melphalan and 
total body irradiation will destroy the hematopoietic 
ability of the patient's marrow, and leave the patient^ 
susceptible to a wide variety of infections and bleeding 
complications until the transplanted marrow and peripheral 
blood stem cells engraft. Aggressive supportive care as 
described above will be used to prevent all known avoidable 
risk. However, a small percentage of patients (5-10% based 
on previously reported studies) may die as a direct result 
of transplant-related complications. These include 
infections, bleeding, veno-occlusive disease of the liver, 
and failure to engraft. Patients will be required to be 
hospitalized for up to three months, and will endure 
discomforts including reverse isolation, severe mucositis 
and related inability eat' or drink, "hAusea and vomiting, and 
many, other high-dose therapy ; and- transplant-related side- 
effects. These discomforts and risks are fully explained in 
the consent form. We expect no' toxicity unique to this 
particular protocol since all components of the treatment 
plan have been used previously in other studies, but 
synergistic interactions that are unexpected could occur, 
and will be closely watched for. 
13 . 0 RESPONSE CRITERIA 
13.1 A complete clinical response (CR) will be defined as 
the complete disappearance of the previously detected serum 
and/or urine monoclonal immunoglobulin biomarker on at least 
Recombinant DNA Research, Volume 16 
[59] 
